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Introduction 
 
Acute heart failure (AHF) due to peripartum cardiomyopathy (PPCM) provides a challenge for 
treating physicians. Moreover, in patients still pregnant therapeutic interventions need always 
to consider both the health of the mother and the foetus. Especially challenging are severe 
forms of PPCM, as the mortality of these women is quite high. The use of inotropic drugs and 
mechanical circulatory support devices may be necessary in the initial phase of severe forms 
of acute PPCM. Many patients, after initial stabilization, recover left ventricular function (1-3). 
Unfortunately, some patients need further mechanical circulatory support or urgent heart 
transplantation despite maximal therapy. In addition, the time frame and extent of recovery is 
unpredictable, and patients may suffer from cardiac arrest due to ventricular fibrillation in the 
first months after diagnosis (4). The clinical course may be further aggravated by atrial and/or 
ventricular thrombus formation with subsequent cardio-embolic complications (5). 
As evidence-based data from randomized clinical trials are scarce, in this practical guidance 
we summarize recent data and clinical experience in the treatment of patients with severe 
acute PPCM to help physicians in the diagnosis, acute treatment and long-term management 
of these young critically ill patients. 
 
Definition and pathophysiology 
The Working Group on peripartum cardiomyopathy of the Heart Failure Association (HFA) of 
the European Society of Cardiology (ESC) recently proposed a new simplified definition of 
PPCM as an idiopathic cardiomyopathy frequently presenting with heart failure secondary to 
left ventricular (LV) systolic dysfunction (LV ejection fraction <45%) towards the end of 
pregnancy or in the months following delivery, if no other cause of heart failure is found (1). 
Since no specific test to confirm PPCM exists, it remains a diagnosis of exclusion. In 
particular, aggravation of pre-existing heart disease by pregnancy-mediated haemodynamic 
changes should be differentiated from PPCM. 
The pathophysiology of PPCM remains poorly understood. The current status of knowledge 
of the pathophysiological mechanisms of PPCM has been published elsewhere (3,5). A “two-
hit” model of angiogenic imbalance in the heart during the peripartal period has recently been 
proposed, combining systemic anti-angiogenic signals during late pregnancy and host 
susceptibility through insufficient local pro-angiogenic defences in the heart (1-3,6). 
Angiogenic imbalance can further be triggered by oxidative stress activating cathepsin D, a 
protease responsible for the cleavage of the nursing hormone prolactin into the angiostatic 
and pro-apoptotic 16-kDa subfragment (4,7).  
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Clinical presentation of acute PPCM 
Most patients admitted with PPCM present typical symptoms of AHF associated with signs of 
congestion. Because early signs and symptoms of heart failure in PPCM patients may mimic 
physiological changes occurring during/after pregnancy, delayed diagnosis may occur. The 
differential diagnosis of acute PPCM includes myocarditis, pre-existing cardiomyopathy, valve 
disease or congenital heart disease. In case of cardiogenic shock, pregnancy-associated 
myocardial infarction, pulmonary embolism and amniotic liquid embolism should be 
immediately ruled out to provide adequate care (Table 1).  
 
Evaluation of acute PPCM 
As for any AHF, initial evaluation of patients with suspected acute PPCM includes two parts, 
which should be performed simultaneously to allow timely diagnosis and treatment delivery: 
evaluation of the cardiopulmonary distress and confirmation of the diagnosis with additional 
tests.  
 
Evaluation of cardiopulmonary distress 
Evaluation of the cardiopulmonary distress is crucial because it will influence subsequent 
treatment and patients’ allocation. The presence of criteria defining cardiopulmonary distress 
should lead to intensive cardiac care unit admission: haemodynamic instability (systolic blood 
pressure <90 mmHg, heart rate >130/min or <45/min), respiratory distress (respiratory rate 
>25/min; peripheral oxygen saturation <90%) or signs of tissue hypoperfusion with abnormal 
cellular oxygen metabolism (increased blood lactate >2.0 mmol/L; low central-venous oxygen 
saturation <60 %, if available; altered mental state; cold, clammy, mottled skin; oliguria <0.5 
ml/kg/h) (1,8).  
 
Confirmation of the diagnosis 
Since PPCM is a diagnosis of exclusion, several additional tests should be performed (see 
below). This should not delay the start of treatment, which should be started as soon AHF is 
confirmed. 
An electrocardiogram should be performed in all patients with suspected PPCM as it has high 
negative predictive value and might help identifying the cardiac origin of dyspnoea. Indeed, 
despite the fact that no specific ECG pattern for PPCM seems to exist, at initial evaluation, 
the ECG is rarely normal and repolarization abnormalities are common (4,9,10). Patients with 
acute PPCM usually have elevated plasma concentrations of natriuretic peptides (11,12). 
Measurement of natriuretic peptides may help during screening for identifying a cardiac origin 
of dyspnoea, although it does not help in the differentiation of PPCM from other 
cardiomyopathies. More specific biomarkers would be helpful to allow a faster and more 
reliable diagnosis of PPCM but these are are yet to be adequately defined. Echocardiography 
is indicated as soon as possible, in all cases of suspected PPCM to confirm the diagnosis, 
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assess concomitant or pre-existing cardiac disease, exclude complications of PPCM (e.g. LV 
thrombus) and obtain prognostic information.  
Cardiac magnetic resonance imaging (MRI) is not routinely needed, but can be performed 
after stabilization in case additional information, not available with echocardiography, is 
needed. However, administration of gadolinium to assess late enhancement, should be 
avoided until after delivery, unless absolutely necessary. Endomyocardial biopsy does not 
add any diagnostic or prognostic information in case of PPCM but can be used to exclude 
acute myocarditis after delivery. Only a few PPCM cases have been related to myocarditis so 
far (13), but myocarditis may underlie cases of dilated cardiomyopathies and acute heart 
failure that can occur or worsen during pregnancy and specific immunosuppressive or 
immune-modulatory treatments may be helpful for some forms of myocarditis (14). 
 
Management of acute PPCM 
The management of heart failure around pregnancy is challenging and in the absence of 
evidence-based data, the initial management of patients with PPCM is similar to the treatment 
of AHF of other aetiologies (15,16). Interdisciplinary approaches of cardiologists, intensivists, 
obstetricians, neonatologists, anaesthetists and cardiac surgeons are necessary in cases of 
severe AHF. Prespecified protocols of interdisciplinary work-up of these patients are helpful 
(Figure 1) (17). Timely diagnosis and treatment delivery are crucial. Figure 2 summarizes the 
recommended treatment algorithm for patients with acute PPCM. Of note, the initial treatment 
of patients with severe forms of acute PPCM is significantly different to those of stable 
patients. 
 
Initial management of acute PPCM with cardiopulmonary distress and/or 
haemodynamic instability 
Patients with signs of cardiopulmonary distress and/or circulatory shock need rapid and more 
aggressive therapy and should be admitted to the intensive cardiac care unit. Initial therapy 
includes five main elements: optimization of the preload, optimization of oxygenation, 
restoration of haemodynamics with inotropes and/or vasopressors, urgent delivery if heart 
failure occurs during pre-partum and consideration of adjunctive therapies with bromocriptine 
(2.5 mg twice daily for 2 weeks followed by 2.5 mg per day for 6 weeks).  
Optimization of preload includes, depending on the clinical scenario, administration of fluids 
or diuretics. If there is no sign of overt fluid overload, a fluid challenge (250-500 ml over 15-30 
minutes) is recommended, especially in patients with intravascular depletion secondary to 
peripartal blood loss or over-aggressive diuretic therapy. In the presence of signs of 
congestion, intravenous diuretics should be administered. In patients with systolic blood 
pressure >110 mmHg, intravenous vasodilators (e.g. nitrates) should be started.  
In the same time, oxygenation should be optimized (target peripheral oxygen saturation, 
SpO2 >95%). Non-invasive ventilation (NIV) reduces respiratory distress and may decrease 
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intubation and mortality rates (18). Intubation with mechanical ventilation should be 
considered in case of altered mental state or persistent hypoxaemia. 
In the presence of signs of cardiogenic shock, haemodynamics should be rapidly restored to 
avoid irreversible organ damage. Inotropes and vasopressors may be considered, although 
the use of catecholamines is associated with adverse effects in patients with advanced heart 
failure or cardiogenic shock (19,20). Experimental evidence and clinical experience suggest 
that catecholamines such as dobutamine are less favourable in PPCM patients due to 
metabolic compromise (21). Therefore, catecholamines should be avoided whenever possible 
or used only with extreme caution. Levosimendan, in contrast to dobutamine and adrenaline, 
does not increase myocardial oxygen demand and may be considered as the preferred 
inotropic agent as continuous infusion of 0.1 µg/kg/hour for 24 hours without an initial loading 
dose (bolus) for patients with severe PPCM (22). A recent small study including 28 patients 
showed that the use of levosimendan in patients with PPCM induced rapid haemodynamic 
recovery and profound decongestive effects (23). In case levosimendan is unavailable, 
dobutamine is the other option while adrenaline should be avoided.  As for other causes of 
shock, noradrenaline should be the first-line vasopressor. 
Patients with haemodynamic instability despite treatment should undergo urgent delivery 
irrespective of gestation duration. Caesarean section with combined spinal and epidural 
analgesia and involvement of an experienced interdisciplinary team are recommended. 
The administration of adjunctive therapies with the prolactin blocker bromocriptine has shown 
promising results in several case-series and in a small proof-of-concept study (24) and should 
be considered for patients with cardiopulmonary distress. The starting dose of bromocriptine 
is usually 2.5 mg twice daily, but an increased dose may be necessary to lower prolactin 
levels in selected cases (see below).  
As thromboembolic events have been reported during the use of bromocriptine (albeit mostly 
at higher dosages), bromocriptine treatment should always be accompanied by at least 
prophylactic anticoagulation with heparin (25). Anticoagulation with heparin should also be 
started in all patients with acute PPCM and severely reduced LV systolic function (LVEF 
≤35%). Indeed, the combination of reduced ejection fraction and the procoagulant activity 
during the peripartal phase expose patients to a clinically important risk of cardioembolic 
events. 
In general, patients with severe distress should be transferred early to an experienced centre 
whenever possible. For patients with persistent haemodynamic instability despite medical 
treatment, mechanical circulatory support should be considered (see below).  
 
Advanced management of severe acute PPCM 
Implantation of a mechanical circulatory support should be considered early as a rescue 
therapy in patients who cannot be stabilized with medical therapy alone. 
If necessary, a device for temporary support should be implanted in the acute phase, either 
as “bridge-to-recovery”, if ventricular function improves during the subsequent days and 
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weaning can be achieved, or as “bridge-to-bridge”, if haemodynamic impairment persists and 
circulatory support has to be ensured by switching to a more durable (and usually more 
invasive) device. Because of the higher proportion of patients with at least partial recovery of 
ventricular function compared to other cardiomyopathies, an initial “bridge-to-transplantation” 
strategy is seldom necessary.  
Since several devices exist and there is little evidence about which device should be 
preferred (26), we provide here an overview of some devices based on experts’ opinion.  
For the choice of the initial device several factors should be taken into account (needed 
haemodynamic support, periprocedural risks, costs), but the oxygenation status of the patient 
plays a central role. If the patient is adequately oxygenated, percutaneous (e.g. intra-aortic 
balloon pump, Impella®) or surgical (e.g. CentriMag®, AbiomedBVS 5000®) devices can be 
used to restore circulation. In contrast, in presence of impaired oxygenation other devices 
with integrated oxygenation should be used (e.g. TandemHeart®, veno-arterial extracorporeal 
membrane oxygenation). Most importantly, as the treatment of patients on mechanical 
circulatory support is very challenging, the choice of the device should also consider the local 
availability and the experience of the involved care team (physicians, nurses, perfusionists). 
Percutaneous devices offer the advantage of fast and easier placement and removal without 
the need for open surgery, but complications related to the access site (bleeding, infection, 
ischaemic limbs) are not uncommon. Intra-aortic balloon pump (IABP) provides less 
haemodynamic support compared to other devices, but on the other hand is easily placed 
and needs less strict anticoagulation. Given the negative results of the IABP-SHOCK II trial 
and the lacking data in PPCM, the value of this device in patients with severe PPCM is 
uncertain, although it is used in selected cases by some centres (27). The Impella® rotary 
pump is an alternative percutaneous device for temporary support. It is inserted 
percutaneously from the femoral artery and is placed in the left ventricle through the aortic 
valve. Depending on the model, it provides a higher degree of haemodynamic support 
compared to IABP (up to 5 L/min) but is associated with haemolysis and, especially in the 
context of PPCM, where a procoagulant state is frequent, a stricter anticoagulation regime 
than for IABP is needed (28). In a small trial in patients with cardiogenic shock complicating 
myocardial infarction, there was no difference in terms of survival between IABP and 
Impella® (29). Clinical experience in several PPCM patients with the Impella 3.5 device 
suggests effective LV support over up to 7-10 days when used as bridge to recovery in most 
patients. The marked decrease in the need for catecholamines may importantly contribute to 
the beneficial outcome observed in several patients (Fig. 3). The TandemHeart® device 
offers similar haemodynamic support as Impella® (up to 5 L/min) with additional improvement 
in oxygenation. The placement of this device is performed percutaneously in the 
catheterization laboratory but it requires a more complex placement with atrial transseptal 
puncture. No evidence of improved outcomes in patients with cardiogenic shock receiving 
TandemHeart® compared to IABP exists (30,31). 
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Extracorporeal membrane oxygenation (ECMO) with veno-arterial cannulation offers the 
maximal available haemodynamic effect with biventricular support and additional 
improvement in oxygenation (32). As increased prolactin levels during ECMO treatment have 
been reported, which may be specifically detrimental in patients with PPCM (33), effective 
suppression of prolactin under sequential measurements of prolactin levels could be 
considered in this particular situation with bromocriptine doses up to 10 mg twice daily. 
After the initial phase, if no weaning from mechanical circulatory support can be achieved 
after a maximum of 7-10 days, a switch to a durable device should be planned. As for 
temporary support, several devices exist and little evidence is available to guide the choice of 
the optimal device. Special attention should be given to right ventricular function. In the 
presence of impaired right ventricular function, a biventricular assist device (BiVAD or total 
artificial heart) may be chosen (e.g. Berlin Heart EXCOR®). Alternatively, several strategies 
of transient right ventricular support in patients after LVAD implantation have been adopted in 
different centres (e.g. veno-arterial ECMO, Impella® RP or similar). In patients with preserved 
right ventricular function, left ventricular assist devices (LVAD) should be preferred. The most 
commonly used devices are the continuous-flow axial (HeartMate II ®) and centrifugal 
(HeartWare®) LVADs which have shown promising results in patients with end-stage heart 
failure (34-36). Given the high likelihood of at least partial recovery of ventricular function in 
PPCM, temporary devices should always be the preferred initial strategy. Cardiac 
transplantation is reserved for patients where mechanical circulatory support is not possible 
or satisfactory ventricular recovery after 6-12 months is not achieved. Post-transplant 
outcomes in women with PPCM appear to be worse than in other recipients: in particular, 
women with PPCM show higher mortality, a higher incidence of rejection with shorter graft 
survival and higher rates of re-transplantation (37). 
 
Management of acute PPCM without cardiopulmonary distress 
The initial treatment of patients with confirmed PPCM without cardiopulmonary distress 
depends on the timepoint of onset. Patients who present after delivery should be treated 
according to the ESC guidelines for heart failure (38). For patients presenting during 
pregnancy joint cardiac and obstetric care in observance of the ESC guidelines for 
management of cardiovascular diseases in pregnancy are recommended (39). 
During pregnancy ACE-inhibitors, angiotensin receptor blockers (ARBs) and renin inhibitors 
are contraindicated because of foetal toxicity. Hydralazine and nitrates can be used instead. 
After delivery, ACE-inhibitors can be started, but during breastfeeding captopril or enalapril 
should be preferred. Despite an increased risk of foetal growth restriction, betablockers are 
indicated in all patients in stable conditions with metoprolol succinate being the preferred 
agent (39,40). Mineralocorticoid receptor antagonists should be avoided during pregnancy 
and lactation but should be started afterwards in stable patients. Diuretics should be 
administered with caution during pregnancy as they may impair perfusion of the placenta. 
Recommendations for drug use during pregnancy and breastfeeding are summarized in 
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Table 21 of the ESC guidelines for management of cardiovascular diseases in pregnancy 
(39). 
 
Bromocriptine in addition to heart failure therapy should be considered because it has shown 
promising results with improved LV systolic function and clinical outcomes in several case-
series and in a small prospective proof-of-concept study (24). In the retrospective non-
randomized German PPCM Registry, treatment with betablockers, ACE inhibitors and 
bromocriptine (2.5 mg twice daily for 2 weeks followed by 2.5 mg per day for 6 weeks) was 
associated with favourable outcomes (41).  A German study with 60 patients randomized 
either to short-term or long-term treatment with bromocriptine has terminated patient 
enrolment and results will be available in the near future  (42). Anticoagulation with heparin 
should be started in all patients with acute PPCM treated with bromocriptine and in those with 
severely reduced LV systolic function (LVEF ≤35%) (25).  
While diuretics should be tapered when possible after stabilization and when LVEF improves, 
ACE inhibitors, betablockers and MRAs should probably be given in guideline-based dosages 
and not discontinued during the first 12 months after complete recovery of LV dimensions and 
systolic function. Earlier, stepwise discontinuation of heart failure therapy might be considered 
if both complete recovery of ventricular function and normal exercise response are achieved. 
Ivabradine should be given according to established indications. Furthermore, early treatment 
with Ivabradine even before or in parallel with betablockers may be considered, as it appears 
to be safe and effective (Figure 3, (43)).  
As relapses have been observed after recovery, tapering of the disease modifying heart 
failure drugs should be performed under close assessment of systolic function (3,5). 
Joint cardiologic and obstetric management including counselling on the potential risk of 
PPCM recurrence with futures pregnancies are recommended. 
 
Prevention of sudden cardiac death 
Despite increasing knowledge about epidemiology and pathophysiology of PPCM, mortality 
rates are not well described and may range from less than 5% up to 50%. It is assumed that 
about a fourth of deaths is caused by ventricular tachyarrhythmia, mostly occurring during the 
first 6 months, and therefore optimal management may prevent a substantial number of 
deaths (4). 
Severely impaired ventricular function is associated with increased risk of life-threatening 
arrhythmias. Current ESC guidelines for the treatment of heart failure recommend 
implantation of an ICD for primary prevention in patients with symptomatic heart failure and 
LVEF ≤35% despite optimal pharmacological treatment or for secondary prevention in patient 
with documented ventricular arrhythmia causing haemodynamic instability (38).  
In the context of PPCM, where young women with the potential of complete recovery of 
ventricular function are involved, decisions about implantation of an ICD should be taken with 
caution. After diagnosis of PPCM, clinicians are faced with the uncertainty about the 
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subsequent evolution of ventricular function. Therefore, the related decision whether to 
implant an ICD or not may be very challenging.  
Several publications reported recovery of LV function in at least 50% of patients within 6 
months after diagnosis (44,45). However, a Turkish study reported delayed recovery (after 6 
months) in a significant proportion of patients (46). A recent retrospective study from the 
United States showed complete recovery of LV function in 23% of patients and partial 
recovery in another 19% over a mean duration of 33±21 months, confirming frequent delayed 
recovery over 6 months (83%) (47). In this study, Afro-American women showed lower rates 
of recovery compared to Caucasians and postpartum diagnosis was a predictor of good 
recovery. In a South African study, age and low LV end-diastolic diameter were predictors of 
recovery, whereas LVEF was not (48).  
In light of these data, early implantation of an ICD in patients with newly diagnosed PPCM is 
not appropriate. However, postponement of ICD implantation beyond the timepoint when 
further recovery of ventricular function is unlikely (6-12 months), exposes young mothers to 
an unacceptable risk of sudden cardiac death.  
Novel therapies, such as the wearable cardioverter-defibrillator (WCD) (LifeVest®, Zoll, 
Pittsburgh, PA, USA) are an interesting alternative for the prevention of sudden cardiac death 
in the first months after diagnosis, until a definitive decision about ICD implantation can be 
made. A German study reported their experience with the WCD in patients with PPCM and 
severely reduced left ventricular function. 7 out of 9 women with PPCM and LVEF ≤35% 
received the WCD early after diagnosis. During a cumulative wearing period of 932 days, four 
adequate shocks were delivered for ventricular fibrillation in three patients without any 
inappropriate shock delivery within the first months of diagnosis (4). These results may 
suggest the prescription of the WCD due to the relevant risk for ventricular tachyarrhythmias 
for at least 3-6 months after diagnosis to allow “protected” recovery from severely reduced left 
ventricular function.  
In patients without recovery despite 3-6 months on optimized heart failure therapy a 
conventional recommendation for the primary prophylactic implantation of an ICD applies 
(38,49). In patients without left bundle branch block or symptomatic sick sinus syndrome 
single chamber ICDs are recommended. Subcutaneous ICDs (S-ICD) represent an 
alternative to transvenous systems in these young patients. Subcutaneous systems avoid 
intravascular leads and thus the potential complication of infections leading to endocarditis 
and lead extractions. On the other hand, subcutaneous systems can neither provide 
antitachycardia pacing (ATP) nor post-shock pacing and therefore might not be the optimal 
choice for patients with recurrent ventricular tachycardia successfully terminated by ATP. 
In patients with heart failure, LVEF ≤35% despite optimal medical therapy for at least 3-6 
months and left bundle branch block cardiac resynchronization therapy (CRT) is indicated, 
although no large studies have evaluated the value of cardiac resynchronization therapy 
(CRT) in patients with PPCM. Significant improvement of LV function in two PPCM-patients 
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undergoing CRT implantation because of persistent symptomatic LV dysfunction was 
reported (50). 
According to the current ESC guidelines on cardiac resynchronization therapy, in patients 
with symptomatic heart failure, persistent LVEF ≤ 35% and complete left bundle branch block 
(QRS duration >130 ms) CRT should be offered; in patients with wide QRS complex with non-
left bundle branch block morphology (QRS duration >150 ms) CRT may be considered (49). 
Although no data on device therapy in patients with PPCM exist, recommendations of the 
device therapy may be applied as in patients with dilated cardiomyopathy. 
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Figure 1: Example of prespecified protocol of interdisciplinary work-up for acute heart 
failure (AHF) during pregnancy (modified from protocol of Medical School Hannover) 
	
AHF during pregnancy
Status and prognosis of the foetus
Foetus non-viable Foetus viable
Delivery
Parents wish
Maternal and foetal status
Delivery
Induction of lung maturation > 23+5 weeks
initiated if possible before patient transfer to tertiary center
Meeting of the Task force for AHF in pregnancy
 goal: ≤ 15 minutes
members: cardiologist, obstetrician, neonatologist, 
anesthesiologist, cardiac surgeon, operating room coordinator
Pregnancy continued
Maximal HF therapy
Supportive psychotherapy
Maximal HF therapy Monitoring mother/foetus
Tailored HF therapy 
Consider advanced AHF therapy  
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Figure 2: Algorithm Initial Management 
	
Urgent delivery (caesarean section)
Severe PPCM with cardiopulmonary distress
Consider mechanical circulatory support
if refractory cardiopulmonary distress
Recovery?
Transplantation Weaning
Optimize preload
 Volume vs. diuretics; vasodilators if SBP >110 mmHg
Optimize oxygenation
Consider NIV, invasive ventilation if SpO2 <95%
Add inotropes and/or vasopressors 
Consider levosimendan 0.1 mcg/kg/min during 24 h
Consider bromocriptine (2.5 mg bid)
Initial evaluation
Assess cardiopulmonary distress
SBP < 90 mmHg; HR > 130/min or < 45/min
RR > 25/min; SpO2 < 90%
Lactate > 2.0 mmol/L; ScvO2 < 60%
Altered mental state; cold skin; oliguria (< 0.5 ml/kg/min)
Confirm diagnosis
ECG
Blood tests incl. natriuretic peptides
Echocardiography, lung ultrasound
Consider additional tests to exclude differential diagnoses
PPCM without cardiopulmonary distress
Antepartum Postpartum
HF therapy
Hydralazine
Nitrates
BB (metoprolol)
Consider diuretics
HF therapy
ACEi (or ARB)
BB
Spironolactone
Diuretics
Consider ivabradine
Consider delivery
(vaginal delivery with PDA)
Consider bromocriptine
(2.5 mg bid)
Consider WCD therapy 
if LVEF ≤ 35% 
Continue HF therapy 
for ≥ 12 months after recovery of LV-function
  
 
 
Legend: 
ACEi ACE-inhibitor - ARB angiotensin receptor blocker - BB betablocker - BiVAD bi-ventricular assist 
device - ECG electrocardiogram - ECMO extracorporeal membrane oxygenation - HF heart failure - HR 
heart rate - LVAD left-ventricular assist device – LVEF left-ventricular ejection fraction - NIV non-
invasive ventilation - PDA peridural anesthaesia - RR respiratory rate - SBP systolic blood pressure - 
SpO2 peripheral oxygen saturation – WCD wearable cardioverter-defibrillator 
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Figure 3:  Example of the management of a PPCM patient with cardiogenic shock in the 
ICU 
 
0
50
PAWP 
(mmHg)
Levosimendan
Treatment day
Impella
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Bisoprolol
Esmolol
Ivabradine
Eplerenone
Enalapril
Valsartan
Extubation
Furosemide i.v.
Torasemide
Bromocriptine 2.5 mg bid 2.5 mg
Heparine
0
0.01
0.02
Norepinephrine
(mg/kg/h)
0
0.3
0.6
Dobutamine
(mg/kg/h)
 
 
 
Legend: 
Figure depicts the management of a patient with newly diagnosed PPCM in cardiogenic shock with 
severely reduced ejection fraction requiring mechanical ventilation and high dose vasopressor 
(norepinephrine), and inotropic support (dobutamine) at the acute presentation. Upon referral to the 
Acute and Advanced Heart Failure Unit of Medical School Hannover, temporary circulatory support with 
the Impella CP® rotary pump was initiated with concurrent invasive haemodynamic monitoring including 
pulmonary artery wedge pressure (PAWP) by means of a Swan-Ganz catheter. Note the decline of 
catecholamine dosage and PAWP after insertion of the Impella CP® rotary pump. Additionally, two 
cycles of 24-hour infusion of levosimendan were administered with an interval of one week, and diuretic 
therapy was given throughout the intensive care. After 10 days, when haemodynamic stabilisation was 
achieved, the patient could be extubated and standard heart failure therapy including ACE-inhibitor 
(later replaced by ARB due to cough), MRA, betablocker was established. Heart rate reduction with 
ivabradine was initiated early during ICU course. The patient was treated with a wearable cardioverter-
defibrillator for 6 months and had an uneventful course; ejection fraction showed a partial recovery 
during the following 6 months. 
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Table 1: Peripartal acute dyspnoea: differential diagnosis of acute PPCM  
 
 PPCM Pre-existing 
CMP, valve 
disease or 
congenital 
heart disease 
Pregnancy-
associated 
myocardial 
infarction 
Pulmonary 
embolism / 
Amniotic liquid 
embolism 
Myocarditis 
History  Most 
commonly 
post-partal 
onset of 
dyspnea 
 Earlier onset 
(during 2nd 
trimester) 
 Sometimes 
family history 
 Retrosternal 
chest pain, 
abdominal 
discomfort, 
nausea 
 Pleuritic 
chest pain 
 Infection 
Biomarkers  Elevated 
natriuretic 
peptides 
 Elevated 
natriuretic 
peptides 
 Elevated 
troponin 
 Elevated D-
Dimer, 
troponin, 
natriuretic 
peptides 
 Elevated 
troponin 
Possibly. 
elevated 
natriuretic 
peptides 
Echocardiography  Left and/or 
right 
ventricular 
dysfunction 
 Evidence of 
pre-existing 
valve disease 
or congenital 
defect 
 Regional 
hypokinesis / 
akinesis 
 Right 
ventricular 
dysfunction, 
elevated RV 
pressure, 
McConnell’s 
sign 
 Regional or 
general 
hypokinesis 
Additional tests  Consider MRI  Consider MRI 
 Consider 
genetic test 
 Coronary 
angiography 
 CT-scan or. 
V/Q 
scintigraphy; 
consider 
angiography 
 MRI 
 Consider 
myocardial 
biopsy 
 
 
 
Box: Peculiarities in the management of AHF caused by PPCM 
- Multidisciplinary approach with focus on health of mother and foetus. 
- Avoidance of HF drugs with foetal toxicity during pregnancy (i.e. ACE-
inhibitors/ARBs, MRAs) and breastfeeding (MRAs), thereafter standard HF therapy. 
- Consideration of bromocriptine (2.5 mg twice daily for 2 weeks, followed by 2.5 mg 
per day for 6 weeks) in addition to standard heart failure therapy. 
- Anticoagulation with heparin to avoid cardio-embolic complications in patients with 
LVEF ≤35% or treated with bromocriptine (if no contraindication exists). 
- In case of cardiogenic shock, consideration of levosimendan (0.1 µg/kg/min for 24h) 
instead of catecholamines as first-line inotropic drug. Early transfer to experienced 
centre. Early evaluation of mechanical circulatory support according to the centre’s 
experience. 
- Prevention of sudden cardiac death, early consideration of wearable cardioverter-
defibrillator devices in patients with LVEF ≤ 35%. 
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